Related Experiment Video
Updated: Aug 14, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
[Treatment options in deep vein thrombosis]
1Medizinische Klinik IV Max-Ratschow-Klinik für Angiologie Städtisches Klinikum Darmstadt. Rupert.Bauersachs@Klinikum-Darmstadt.de
Deep vein thrombosis (DVT) treatment focuses on preventing embolism and recurrence. Initial therapy uses low molecular weight heparin (LMWH) or fondaparinux, bridging the gap until vitamin K antagonists take full effect.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Context:
- Deep vein thrombosis (DVT) poses significant risks of embolism and recurrence.
- Effective management requires bridging anticoagulation strategies.
- Vitamin K antagonists (VKAs) have a delayed onset of action.
Purpose:
- To outline the initial therapeutic strategies for deep vein thrombosis.
- To describe the role of anticoagulants in bridging therapy.
- To address secondary prophylaxis in specific patient populations.
Summary:
- Low molecular weight heparin (LMWH) or fondaparinux are used for initial acute treatment of DVT.
- These agents bridge the therapeutic gap until VKAs achieve full effect.
- Dose-adjusted LMWH is an alternative for secondary prophylaxis when VKAs are contraindicated or during pregnancy.
- Compression therapy is recommended for preventing post-thrombotic syndrome.
Impact:
- Ensures immediate anticoagulation to prevent serious complications.
- Provides safe and effective treatment options for diverse patient groups.
- Aims to reduce long-term morbidity associated with DVT.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

